Status:
TERMINATED
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
Lead Sponsor:
Hebei Medical University
Conditions:
Heart Failure, Congestive
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ACE inhibitor is more effective in reverse left ventricula...
Detailed Description
In the investigators' recent daily clinical practice, they found that the larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ACE inhibitor and the highest tolera...
Eligibility Criteria
Inclusion
- New York Heart Association (NYHA) Functional class Ⅲ or Ⅳ
- Left Ventricular Ejection Fraction (LVEF) \<35%
- Nonischemic cardiomyopathy
- Preserved renal function: Cr ≤2.5 mg/dL in males; Cr ≤2.0mg/dL in females
Exclusion
- Hyperkalemia (≥5.0 mEg/L)
- Left ventricular systolic dysfunction with pericardial diseases, congenital heart diseases, pulmonary heart diseases, heart valvular diseases, acute coronary syndrome and short life expectancy.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00125437
Start Date
September 1 2005
End Date
September 1 2009
Last Update
July 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050031